Research Alliance Corporation III Prices IPO at $10 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2026
0mins
Source: seekingalpha
- IPO Pricing: Research Alliance Corporation III has successfully priced its initial public offering at $10 per share for 7.5 million Class A ordinary shares, raising a total of $75 million to fund future acquisitions.
- Trading Launch: The company expects its shares to begin trading on the Nasdaq Capital Market on May 20 under the ticker symbol “RACC”, providing new investment opportunities for investors.
- Acquisition Focus: Research Alliance Corporation III intends to target acquisitions in the healthcare and healthcare-related sectors, aiming to leverage industry growth potential to drive future company development.
- Expected Closing: The offering is anticipated to close on May 21, subject to customary closing conditions, ensuring the funds are secured to support subsequent strategic initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RACC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RACC
Wall Street analysts forecast RACC stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 10.400
Low
Averages
High
Current: 10.400
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three IPOs and Seven SPACs Priced This Week
- Successful Pricing of Lincoln Financial: Lincoln Financial (LCLN) priced at $421 million, achieving a market cap of $2.2 billion, indicating strong demand in the private capital markets despite geopolitical and private credit concerns affecting peers.
- Direct Listing of AMASS Brands: Beverage company AMASS Brands (AMSS) completed its direct listing on Nasdaq, yet its stock fell 52% from the $8.98 price of its last funding round, reflecting market caution towards its premium beverage platform.
- Conexeu Sciences Surge: Medical device developer Conexeu Sciences (CNXU) completed a direct listing on Nasdaq, with its stock soaring 260% from the $4.00 price of its most recent private placement, showcasing investor enthusiasm for its unique regenerative medical technology.
- SPACs Pricing Overview: Seven SPACs priced this week, with Oceanhawk Acquisition (OHACU) raising $160 million and Aperture AC (APURU) raising $90 million, demonstrating ongoing market interest in blank check companies despite an uncertain overall market environment.
See More
Research Alliance Corporation III Prices IPO at $10 per Share
- IPO Pricing: Research Alliance Corporation III has successfully priced its initial public offering at $10 per share for 7.5 million Class A ordinary shares, raising a total of $75 million to fund future acquisitions.
- Trading Launch: The company expects its shares to begin trading on the Nasdaq Capital Market on May 20 under the ticker symbol “RACC”, providing new investment opportunities for investors.
- Acquisition Focus: Research Alliance Corporation III intends to target acquisitions in the healthcare and healthcare-related sectors, aiming to leverage industry growth potential to drive future company development.
- Expected Closing: The offering is anticipated to close on May 21, subject to customary closing conditions, ensuring the funds are secured to support subsequent strategic initiatives.
See More
Research Alliance III Raises $75 Million for Healthcare SPAC
- Funding Size: Research Alliance III successfully raised $75 million by offering 7.5 million shares at $10 each, indicating strong market interest and investment enthusiasm in the healthtech sector.
- Increased Share Offering: Originally planning to offer 5 million shares, the company increased its offering earlier this month, reflecting robust demand for its investment opportunities, potentially providing greater financial support for future acquisitions.
- Industry Focus: The SPAC targets healthcare-related industries, specifically drug development, commercialization, diagnostics, and healthcare technology services, aiming to drive innovation and growth through acquisitions, thereby strengthening RA Capital's influence in the sector.
- Transaction Arrangement: The company will trade on Nasdaq under the symbol RACC, with Leerink Partners acting as the sole bookrunner for the deal, ensuring a smooth fundraising process.
See More
Research Alliance Corporation III Announces IPO Pricing
- IPO Pricing Details: Research Alliance Corporation III has announced the pricing of its initial public offering at $10.00 per share for 7.5 million Class A ordinary shares, with the offering expected to close on May 21, 2026, reflecting market confidence in its future business combinations.
- Listing Information: The shares will be listed on the Nasdaq Capital Market under the ticker symbol 'RACC', providing the company with broader access to capital and supporting its future acquisition strategies.
- Management Team Background: Sponsored by an affiliate of RA Capital Management, the leadership of CEO Matthew Hammond, PhD, and COO Henry Stusnick is expected to provide a competitive edge in the healthcare sector, enhancing investor confidence in the company's strategic direction.
- Investor Participation: The financing has attracted participation from several institutional investors, including ADAR1 Capital and Venrock Healthcare Capital Partners, indicating strong market interest and support, which further solidifies the company's capital foundation.
See More
Three IPOs and Seven SPACs Priced This Week
- Successful Pricing of Lincoln Financial: Lincoln Financial (LCLN) priced at $421 million, achieving a market cap of $2.2 billion, indicating strong demand in the private capital markets despite geopolitical and private credit concerns affecting peers.
- Direct Listing of AMASS Brands: Beverage company AMASS Brands (AMSS) completed its direct listing on Nasdaq, yet its stock fell 52% from the $8.98 price of its last funding round, reflecting market caution towards its premium beverage platform.
- Conexeu Sciences Surge: Medical device developer Conexeu Sciences (CNXU) completed a direct listing on Nasdaq, with its stock soaring 260% from the $4.00 price of its most recent private placement, showcasing investor enthusiasm for its unique regenerative medical technology.
- SPACs Pricing Overview: Seven SPACs priced this week, with Oceanhawk Acquisition (OHACU) raising $160 million and Aperture AC (APURU) raising $90 million, demonstrating ongoing market interest in blank check companies despite an uncertain overall market environment.
See More
Research Alliance Corporation III Prices IPO at $10 per Share
- IPO Pricing: Research Alliance Corporation III has successfully priced its initial public offering at $10 per share for 7.5 million Class A ordinary shares, raising a total of $75 million to fund future acquisitions.
- Trading Launch: The company expects its shares to begin trading on the Nasdaq Capital Market on May 20 under the ticker symbol “RACC”, providing new investment opportunities for investors.
- Acquisition Focus: Research Alliance Corporation III intends to target acquisitions in the healthcare and healthcare-related sectors, aiming to leverage industry growth potential to drive future company development.
- Expected Closing: The offering is anticipated to close on May 21, subject to customary closing conditions, ensuring the funds are secured to support subsequent strategic initiatives.
See More
Research Alliance III Raises $75 Million for Healthcare SPAC
- Funding Size: Research Alliance III successfully raised $75 million by offering 7.5 million shares at $10 each, indicating strong market interest and investment enthusiasm in the healthtech sector.
- Increased Share Offering: Originally planning to offer 5 million shares, the company increased its offering earlier this month, reflecting robust demand for its investment opportunities, potentially providing greater financial support for future acquisitions.
- Industry Focus: The SPAC targets healthcare-related industries, specifically drug development, commercialization, diagnostics, and healthcare technology services, aiming to drive innovation and growth through acquisitions, thereby strengthening RA Capital's influence in the sector.
- Transaction Arrangement: The company will trade on Nasdaq under the symbol RACC, with Leerink Partners acting as the sole bookrunner for the deal, ensuring a smooth fundraising process.
See More
Research Alliance Corporation III Announces IPO Pricing
- IPO Pricing Details: Research Alliance Corporation III has announced the pricing of its initial public offering at $10.00 per share for 7.5 million Class A ordinary shares, with the offering expected to close on May 21, 2026, reflecting market confidence in its future business combinations.
- Listing Information: The shares will be listed on the Nasdaq Capital Market under the ticker symbol 'RACC', providing the company with broader access to capital and supporting its future acquisition strategies.
- Management Team Background: Sponsored by an affiliate of RA Capital Management, the leadership of CEO Matthew Hammond, PhD, and COO Henry Stusnick is expected to provide a competitive edge in the healthcare sector, enhancing investor confidence in the company's strategic direction.
- Investor Participation: The financing has attracted participation from several institutional investors, including ADAR1 Capital and Venrock Healthcare Capital Partners, indicating strong market interest and support, which further solidifies the company's capital foundation.
See More
